|January 29, 2009|
Barry Margolin, former chair of the Department of Biostatistics at the UNC Gillings School of Global Public Health, died Jan. 28, 2009, after many years of declining health. <p”>
Born in New York City in 1943, Margolin graduated summa cum laude from City College of New York in 1963 and acquired master’s and doctorate degrees from Harvard University. He served on the Yale University faculty for a decade beginning in 1967, followed by a decade of service as a mathematical statistician at the National Institute of Environmental Health Sciences in Research Triangle Park, N.C.
Margolin joined the UNC biostatistics faculty in 1987 as professor and chair, a position he held until 1999. He also served as director of the biostatistics facility at the UNC Lineberger Comprehensive Cancer Center from 1989 to 1999.
His many professional honors included the American Statistical Association’s Snedecor Award, which honors a person instrumental in developing statistical theory in biometry, and the National Institutes of Health Director’s Award, for leadership, achievement and performance excellence.
“Barry was a world-renowned biostatistician who made substantial contributions to statistical methods for toxicity studies,” said longtime friend and colleague, Clarence E. (Ed) Davis, PhD, professor and former chair of the Department of Biostatistics. “His former students and postdocs continue to contribute to studies of the environment. This is a great loss to the biostatistical community.”
Margolin leaves behind his wife, Constance (Connie) Margolin, and daughter Lauren, as well as many relatives, friends, former students and colleagues around the world.
A funeral is planned Friday, Jan. 30, at 11 a.m. at Howerton-Bryan Funeral Chapel, 1005 W. Main St., Durham, N.C., with interment at the Durham Hebrew Cemetery.
The family will be available for visitation at their home through Wednesday evening, Feb. 4. All who knew him are invited to leave remembrances online.
September 21, 2023 New research conducted by the UNC Gillings School of Global Public Health and the Cleveland Clinic shows that ritonavir-boosted nirmatrelvir (Paxlovid) and molnupiravir (Lagevrio) substantially reduced COVID-19 hospitalization and death among high-risk patients, even against the most recent Omicron subvariants BQ.1.1 and XBB.1.5.